ReviewBevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Section snippets
Identification of VEGF
In 1983, Senger et al. [9] reported the partial purification from the conditioned medium of a guinea-pig tumor cell line of “vascular permeability factor” (VPF), a protein that induced vascular leakage in the skin. Because VPF was not isolated and sequenced, this factor remained molecularly unknown at that time.
In 1989, our laboratory reported the isolation and NH2-terminal sequencing of VEGF, an endothelial cell-specific mitogen, from medium conditioned by bovine pituitary cells [10]. The
The VEGF isoforms
The human VEGF-A gene is organized in eight exons [14], [15]. Alternative exon splicing results in the generation of four main VEGF isoforms, having, respectively, 121, 165, 189, and 206 amino acids following signal sequence cleavage (VEGF121, VEGF165, VEGF189, and VEGF206) [12]. VEGF165 is the predominant isoform. Numerous less frequent splice variants have been also reported, including VEGF145, VEGF183 VEGF162, and VEGF165b (reviewed in [16]).
Alternative splicing regulates the bioavailability
VEGF receptors
There are two VEGF receptor tyrosine kinases (RTKs), Flt-1, known also as VEGFR-1 [27], [28] and KDR, Flk-1, or VEGFR-2 [29], [30], [31].
There is now agreement that VEGFR-2 is the major mediator of the mitogenic, angiogenic, and permeability-enhancing effects of VEGF. For a detailed review of the biological and signaling properties of the VEGF receptors, see [16].
Under some circumstances, VEGFR-1 may function as a “decoy” receptor that sequesters VEGF and prevents its interaction with VEGFR-2
Regulation of VEGF gene expression
Oxygen tension plays a major role in regulating the expression of a variety of genes, including VEGF, and HIF-1 is a key transcriptional regulator of hypoxic responses [40]. A link between the product of the von Hippel–Lindau (VHL) tumor suppressor gene and HIF-1-dependent responses has been established (for review sees [41]). The VHL gene is inactivated in patients with von Hippel–Lindau disease, an autosomal dominant neoplasia syndrome characterized by capillary hemangioblastomas in retina
Role of VEGF in tumor angiogenesis
In situ hybridization studies demonstrate VEGF mRNA expression in many human tumors. These include lung [50], breast [51], gastrointestinal tract [52], renal [53], and ovarian carcinomas [54]. However, the expression of VEGF appears to be variable, not only among different tumor types, but also within the same tumor (for reviews see [8], [16]). Renal cell carcinomas have a particularly high VEGF expression is renal cell carcinoma, in agreement with the notion that inactivating VHL mutations
Preclinical studies
In 1997, we reported the humanization of the murine anti-VEGF Mab A.4.6.1. [78]. Like its murine counterpart, bevacizumab binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, but not mouse or rat VEGF. The binding epitope of bevacizumab has been defined by crystal structure analysis of a complex Fab ligand [79]. The pharmacokinetic properties of bevacizumab in several species have been previously described and are consistent with a typical humanized monoclonal
Ongoing studies and perspectives
For the first-line treatment of metastatic colorectal cancer, the addition of bevacizumab to bolus IFL chemotherapy conferred a clinically meaningful and statistically significant benefit for all study endpoints, including overall survival, progression free survival, and response rate, and was associated with an acceptable side effect profile.
The improvement in survival attributable to bevacizumab is similar or greater than that observed in any Phase III trial for the treatment of colorectal
References (96)
- et al.
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
Biochem. Biophys. Res. Commun.
(1989) - et al.
Human vascular permeability factor. Isolation from U937 cells
J. Biol. Chem.
(1989) - et al.
The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing
J. Biol. Chem.
(1991) - et al.
Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms
J. Biol. Chem
(1992) - et al.
The carboxyl-terminal domain (111–165) of vascular endothelial growth factor is critical for its mitogenic potency
J. Biol. Chem.
(1996) - et al.
Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
J. Biol. Chem.
(1998) - et al.
Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
Biochem. Biophys. Res. Commun.
(1992) - et al.
High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
Cell
(1993) - et al.
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
J. Biol. Chem.
(1994) - et al.
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
Blood
(1996)